Luca Mascitelli, MD; Eddie Vos, MEng
Potential Financial Conflicts of Interest: None disclosed.
Mascitelli L., Vos E.; Analyzing the Results of the Treating to New Targets Study. Ann Intern Med. 2008;148:321-322. doi: 10.7326/0003-4819-148-4-200802190-00020
Download citation file:
Published: Ann Intern Med. 2008;148(4):321-322.
TO THE EDITOR:
The analysis of the TNT trial by Wenger and colleagues (1) suggests benefit from top-dose atorvastatin in patients older than 65 years of age. However, the 22 additional deaths from noncardiovascular causes more than offset the 5 fewer deaths from cardiovascular causes (vs. patients receiving low-dose atorvastatin), a result consistent with the entire TNT study population.
This is ominous considering that this subgroup had the following characteristics at baseline: mean age of 70 years, 82% had angina, 18% had diabetes, 53% had a myocardial infarction, 49% had angioplasty, and 55% had bypass operations.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only